ID   Mel1617-BR
AC   CVCL_DG52
SY   MEL1617-BR; Mel1617BR; Mel1617-R; Mel1617 R
DR   cancercelllines; CVCL_DG52
DR   Wikidata; Q54905150
RX   PubMed=21156289;
RX   PubMed=23285177;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:131882; SB-590885.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=21156289).
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_DG51 ! Mel1617
SX   Male
AG   22Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 9
//
RX   PubMed=21156289; DOI=10.1016/j.ccr.2010.11.023;
RA   Villanueva J., Vultur A., Lee J.T., Somasundaram R.,
RA   Fukunaga-Kalabis M., Cipolla A.K., Wubbenhorst B., Xu X.-W.,
RA   Gimotty P.A., Kee D., Santiago-Walker A.E., Letrero R., D'Andrea K.,
RA   Pushparajan A., Hayden J.E., Dahlman K.B., Laquerre S.G., McArthur G.A.,
RA   Sosman J.A., Nathanson K.L., Herlyn M.;
RT   "Acquired resistance to BRAF inhibitors mediated by a RAF kinase
RT   switch in melanoma can be overcome by cotargeting MEK and
RT   IGF-1R/PI3K.";
RL   Cancer Cell 18:683-695(2010).
//
RX   PubMed=23285177; DOI=10.1371/journal.pone.0052760;
RA   Schayowitz A.B., Bertenshaw G.P., Jeffries E., Schatz T., Cotton J.,
RA   Villanueva J., Herlyn M., Krepler C., Vultur A., Xu W., Yu G.H.,
RA   Schuchter L.M., Clark D.P.;
RT   "Functional profiling of live melanoma samples using a novel automated
RT   platform.";
RL   PLoS ONE 7:E52760-E52760(2012).
//